¿Actúan las estatinas a través de los PPARα?

Hydroxymethylglutaryl-CoA reductase inhibitors, or statins, and fibric acid derivatives, or fibrates, are the two most widely used drug families in the treatment of dyslipidemias. Both statins and fibrates produce beneficial effects that go beyond those that could be expected on the basis of the modification of plasma lipid concentrations produced by the treatment. These effects, known generically as pleiotropic effects, are mainly anti-inflammatory and many of them are common to fibrates and statins. The present review discusses the possible convergence in the molecular pathways producing the pleiotropic effects of fibrates and statins through modulation of the transcriptional activity of PPARα and nuclear factor-κβ.